secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2023-02-01T23:59:59+00:00
Accession:  0000950142-23-000247
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics appoints Elizabeth Keiley as EVP and General Counsel
---------------------------------------------------------------------

- Elizabeth Keiley appointed Executive Vice President and General Counsel, effective immediately.
- Keiley brings legal experience from Entasis Therapeutics, Oxford Immunotec, and Zimmer.
- She will support vTv's capital funding goals and upcoming Phase 3 trials for TTP399.
- vTv is a clinical-stage biopharma focused on oral treatments for type 1 diabetes and cystic fibrosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000095014223000247/0000950142-23-000247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000095014223000247/eh230326253_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-23-000247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer